Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KB-R7943 is a small molecule research compound best known as a selective inhibitor of the reverse mode of the sodium-calcium exchanger (NCX), particularly targeting NCX1 with an IC50 of approximately 0.7 μM. It also inhibits the mitochondrial calcium uniporter (MCU) with a Ki of 5.5 μM, and at higher concentrations can partially block NMDA receptor-mediated currents and inhibit mitochondrial respiratory complex I. KB-R7943 is widely used in pharmacological studies investigating calcium homeostasis, neuronal excitotoxicity, cardiac and neuronal injury, and cell death processes. It can induce apoptosis and cell cycle arrest in cancer cell models, and displays cardioprotective and neuroprotective properties under specific experimental conditions. The compound is not approved for clinical or therapeutic use and is intended for laboratory research only[2][4][5][7][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KB-R7943.